Table 2.
LncRNAs Involved in Chemotherapy Resistance in Breast Cancer
| Drug | lncRNA | Dysregulation | Effect on Drug Resistance | Target/Pathway/Mechanisms | Refs |
|---|---|---|---|---|---|
| Doxorubicin or Adriamycin | Linc00668 | ↑ | Promoting | SND1 | [59] |
| BORG | ↑ | Promoting | NF-κB/DNA damage | [60] | |
| Linc00152 | ↑ | Promoting | EMT | [61] | |
| ARA | ↑ | Promoting | MAPK/cell cycle | [62] | |
| PTENP1 | ↓ | Reversing | PTEN/PI3K/Akt | [63] | |
| MEG3 | ↓ | Reversing | Bax/Bcl-2/apoptosis | [64] | |
| Epirubicin | NONHSAT101069 | ↑ | Promoting | miR-129-5p/TWIST1 | [29] |
| SPRY4-IT1 | ↑ | Promoting | / | [65] | |
| Paclitaxel | FTH1P3 | ↑ | Promoting | miR-206/ABCB1 | [67] |
| CASC2 | ↑ | Promoting | miR-18a-5p/CDK19 | [68] | |
| Linc00511 | ↑ | Promoting | miR-29c/CDK6/cytotoxicity | [69] | |
| MAPT-AS1 | ↑ | Promoting | MAPT | [70] | |
| RP11-770J1.3 | ↑ | Promoting | TMEM25/MRP/BCRP/MDR1/P-gp | [71] | |
| Docetaxel | EPB41L4A-AS2 | ↓ | Reversing | ABCB1 | [72] |
| Cisplatin | SNHG15 | ↑ | Promoting | miR-381 | [74] |
| HCP5 | ↑ | Promoting | PTEN | [75] | |
| 5-Fluorouracil | PRLB | ↑ | Promoting | miR-4766-5p/SIRT1 | [77] |
Notes: “↑” represents upregulation; “↓” represents downregulation; “/” represents not mentioned.
Abbreviation: EMT, epithelial–mesenchymal transition.